Search Results - combination+therapy

6 Results

Sort By:

Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery

Abstract: The invention relates to novel lipid-based nanoparticles (liposomes) for use in targeted, on demand and on site drug delivery. The particles include a wall surrounding a cavity, wherein the wall is comprised of: A lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), dipalmitoylphosphatidylcholine...

Published: 4/8/2024 | Inventor(s): Anu Puri, Robert Blumenthal, Amit Joshi, Darayash Tata, Mathias Viard

Keywords(s): Combination Therapy, Delivery Agent, Infections (bacteria and viruses), Lipid nanoparticle, liposome, On-demand Drug Release, photoactivation, therapeutic delivery

Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Dermatology, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Opthamology, TherapeuticArea > Eye / Ear / Nose / Throat, Collaboration Sought > Licensing, TherapeuticArea > Cardiology

Combination of Near Infrared Photoimmunotherapy Targeting Cancer Cells and Host-Immune Activation

Abstract: Common methods of cancer therapy largely rely on either direct killing of cancer cells or activation of the host immune response to do so, but not both. A recently developed treatment of tumors uses an antibody/photo-absorber, Ab-IR700, with near infrared photoimmunotherapy (NIR-PIT), to selectively kill IR700-bound and NIR-light-exposed cancer...

Published: 4/8/2024 | Inventor(s): Hisataka Kobayashi, Peter Choyke

Keywords(s): antibody-IR700, Combination Therapy, Immunomodulators, Immunotherapy, Kobayashi, Metastasis, Near-Infrared Photo Immunotherapy, NIR-PIT, Photochemical, Tumor Inhibition

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Combination Cancer Therapy with HDAC Inhibitors

Abstract: The clinical promise of cancer immunotherapy relies on the premise that the immune system can recognize and eliminate tumor cells identified as non-self. The success of cancer immunotherapy is limited by tumor immune evasion, preventing long-lasting tumor control. Recent evidence suggests that certain anticancer therapies can alter the biology...

Published: 4/8/2024 | Inventor(s): James Hodge, Sofia Gameiro

Keywords(s): Combination Therapy, CTL, HDAC inhibition, Immunotherapy

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Immunotherapy Combination Treatment Containing both TLR4 and TLR2/6 Agonists, a Checkpoint Inhibitor, and a STING agonist.

Abstract: Melanoma is an aggressive form of skin cancer that commonly becomes metastatic, spreading to nearby tissue or other parts of the body, including distant skin or subcutaneous sites such as the lungs, liver, brain, or bone. Metastatic melanoma is very drug resistant and difficult to treat, and therefore, the prognosis for these patients is poor....

Published: 5/22/2024 | Inventor(s): Md Alam, De Yang, Joost Oppenheim

Keywords(s): cGAMP, Combination Therapy, FSL-1, HMGN1, Immune Checkpoint Inhibitor, Immunotherapy, Melanin-Producing Melanoma, MELANOMA, Oppenheim, RESISTANT, STING Agonist, TLR, TLR2/6, TLR4, TLR4 Agonist, Toll-like receptor, TRL2/6 Agonist

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination

Abstract: Researchers at the National Cancer Institute (NCI) have developed a method of stimulating an immune response in humans at risk for infection by, or already infected with, an Human Immunodeficiency Virus (HIV)-1 retrovirus. This method utilizes deoxyribonucleic acid (DNA) vaccines to stimulate CD8+ T cell immune responses. The DNA vaccine encodes...

Published: 8/5/2024 | Inventor(s): Genoveffa Franchini, Zdenek Hel, George Pavlakis, James Tartaglia

Keywords(s): Combination Therapy, CTL, cytotoxic T lymphocyte, Deoxyribonucleic Acid, DNA vaccine, Franchini, HIV, Human Immunodeficiency Virus, POX VIRUS

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Application > Vaccines

Highly Potent and Selective Deubiquitinating Enzyme Inhibitor

Available for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from...

Published: 7/29/2024 | Inventor(s): Andrew Rosenthal, Ajit Jadhav, Thomas Dexheimer, Anton Simeonov, Qin Liang, Zhihao Zhuang, David Maloney

Keywords(s): CANCER, CANCER THERAPEUTICS, CB5XXX, CB7XXX, CBXXXX, Combination Therapy, CXXXXX, Deubiquitinase, Inhibitors, POTENT, protease inhibitors, SELECTIVE, small molecule, USP1/UAF1

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics